drugset
drugset / Trial / NCT03581903

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

NCT03581903 ↗

Phase 1 Completed 20 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess priming with antigenically mismatched live attenuated A/H7N3 influenza virus vaccine followed by inactivated A/H7N9 influenza virus vaccine in healthy adults.

Timeline

Start
2017-09-19
Primary completion
2018-09-14
Completion
2019-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject H7N3 pLAIV Vaccine 1e+07 unknown Intranasal
Subject H7N9 pIIV Vaccine 30 ug Intramuscular

Indications

influenza